Log In
Print
BCIQ
Print
Print this Print this
 

Kazano, alogliptin/metformin

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionFixed-dose combination of alogliptin plus metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of Action 
Latest Stage of DevelopmentApproved
IndicationDiabetes
Partner

Furiex Pharmaceuticals Inc.
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today